Globus Medical (GMED) Liabilities and Shareholders Equity (2011 - 2026)

Globus Medical (GMED) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $5.4 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 15.46% year-over-year to $5.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.8 billion (up 3.77% YoY) and the FY2025 annual result came in at $5.3 billion, up 0.97% from the prior year.
• Liabilities and Shareholders Equity advanced to $5.4 billion in Q1 2026, from $5.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $5.4 billion in Q1 2026 to a low of $1.9 billion in Q2 2022.
• A 5-year average of $4.0 billion and a median of $5.0 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity soared 170.98% — and 2024, when it retreated 5.04%.
• Tracing GMED's Liabilities and Shareholders Equity over 5 years: stood at $2.1 billion in 2022, then jumped by 144.98% to $5.1 billion in 2023, then advanced by 3.26% to $5.3 billion in 2024, then climbed by 0.97% to $5.3 billion in 2025, then grew by 2.58% to $5.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $5.4 billion (Q1 2026), $5.3 billion (Q4 2025), and $5.1 billion (Q3 2025), per Business Quant data.